Litcius/Paper detail

Cyclic <sup>68</sup> Ga-Labeled Peptides for Specific Detection of Human Angiotensin-Converting Enzyme 2

Matthew F.L. Parker, Joseph Blecha, Oren S. Rosenberg, Michael A. Ohliger, Robert R. Flavell, David M. Wilson

2021Journal of Nuclear Medicine24 citationsDOIOpen Access PDF

Abstract

In this study, we developed angiotensin-converting enzyme 2 (ACE2)–specific, peptide-derived <sup>68</sup>Ga-labeled radiotracers, motivated by the hypotheses that ACE2 is an important determinant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) susceptibility and that modulation of ACE2 in coronavirus disease 2019 (COVID-19) drives severe organ injury. <b>Methods:</b> A series of NOTA-conjugated peptides derived from the known ACE2 inhibitor DX600 were synthesized, with variable linker identity. Since DX600 bears 2 cystine residues, both linear and cyclic peptides were studied. An ACE2 inhibition assay was used to identify lead compounds, which were labeled with <sup>68</sup>Ga to generate peptide radiotracers (<sup>68</sup>Ga-NOTA-PEP). The aminocaproate-derived radiotracer <sup>68</sup>Ga-NOTA-PEP4 was subsequently studied in a humanized ACE2 (hACE2) transgenic model. <b>Results:</b> Cyclic DX-600–derived peptides had markedly lower half-maximal inhibitory concentrations than their linear counterparts. The 3 cyclic peptides with triglycine, aminocaproate, and polyethylene glycol linkers had calculated half-maximal inhibitory concentrations similar to or lower than the parent DX600 molecule. Peptides were readily labeled with <sup>68</sup>Ga, and the biodistribution of <sup>68</sup>Ga-NOTA-PEP4 was determined in an hACE2 transgenic murine cohort. Pharmacologic concentrations of coadministered NOTA-PEP (blocking) showed a significant reduction of <sup>68</sup>Ga-NOTA-PEP4 signals in the heart, liver, lungs, and small intestine. Ex vivo hACE2 activity in these organs was confirmed as a correlate to in&nbsp;vivo results. <b>Conclusion:</b> NOTA-conjugated cyclic peptides derived from the known ACE2 inhibitor DX600 retain their activity when N-conjugated for <sup>68</sup>Ga chelation. In vivo studies in a transgenic hACE2 murine model using the lead tracer, <sup>68</sup>Ga-NOTA-PEP4, showed specific binding in the heart, liver, lungs and intestine—organs known to be affected in SARS-CoV-2 infection. These results suggest that <sup>68</sup>Ga-NOTA-PEP4 could be used to detect organ-specific suppression of ACE2 in SARS-CoV-2–infected murine models and COVID-19 patients.

Topics & Concepts

In vivoChemistryEx vivoBiodistributionPeptideEnzymeCyclic peptideBiochemistryIn vitroBiologyBiotechnologySARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesPhagocytosis and Immune Regulation